Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 4Prostatic Neoplasms 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumour 1Recurrence 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1Healthy Participants 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumours 1Advanced Solid Malignancy, 1Advanced Solid Malignancy 1Advanced Gastric Cancer 1Advanced Cancer 1Adenocarcinoma 1

Interventions

capivasertib 1N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 1Midazolam 1L19-IL2 immunocytokine 1Itraconazole 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumour × capivasertib × Clear all
NCT04958226 2024-01-25

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
21 enrolled
Other solid neoplasm

Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡